Avacta signs new Covid-19 test deal

The Wetherby-based group said the deal will also support Covid-19 testing in low and middle income countries.

Avacta is teaming up with Mologic to accelerate to market Avacta’s AffiDX SARS-CoV-2 lateral flow rapid antigen test.

The pair said the partnership will provide a faster route to market for Avacta’s rapid antigen test by CE marking it for professional use under Mologic’s existing ISO13485 quality system.

The CE mark will then be transferred to Avacta when it receives ISO13485 accreditation, which is expected by the end of next month.

Dr Alastair Smith, chief executive of Avacta, said: “I am very pleased to announce this partnership with Mologic, which follows a close collaboration over recent months.

"The partnership provides Avacta with a low risk route to CE marking our rapid antigen test during the first quarter ahead of achieving our own ISO13485 accreditation.

“I am also delighted that this collaboration provides an opportunity for Avacta to support antigen testing in low and middle income countries through Mologic’s international manufacturing links.

“The longer term collaboration with Mologic, on a range of diagnostic tests, offers a significant potential opportunity for the group. The combination of our technologies to generate a world leading second generation antigen test for SARS-CoV-2 is an exciting possibility."